Year: - Any -2023202220212020201920182017 Items per page 102550 Date Title Nov 30, 2023 Summary ToggleSol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study Nov 28, 2023 Summary ToggleSol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610 Nov 09, 2023 Summary ToggleSol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update Aug 30, 2023 Summary ToggleSol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference Aug 10, 2023 Summary ToggleSol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update Jun 06, 2023 Summary ToggleSol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada May 12, 2023 Summary ToggleSol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update Mar 20, 2023 Summary ToggleSol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference Mar 10, 2023 Summary ToggleSol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments Jan 27, 2023 Summary ToggleSol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
Year: - Any -2023202220212020201920182017 Items per page 102550 Date Title Nov 30, 2023 Summary ToggleSol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study Nov 28, 2023 Summary ToggleSol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610 Nov 09, 2023 Summary ToggleSol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update Aug 30, 2023 Summary ToggleSol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference Aug 10, 2023 Summary ToggleSol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update Jun 06, 2023 Summary ToggleSol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada May 12, 2023 Summary ToggleSol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update Mar 20, 2023 Summary ToggleSol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference Mar 10, 2023 Summary ToggleSol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments Jan 27, 2023 Summary ToggleSol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement Offerings Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last